Publication | Open Access
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
381
Citations
14
References
2017
Year
Cancer ImmunosurveillanceOncologyMelanomaImmunologyTumor ImmunityMetastatic MelanomaImmune SurveillanceAutoimmunityImmune Checkpoint InhibitorImmunotherapyMedicineImmune-related Adverse Events
| Year | Citations | |
|---|---|---|
Page 1
Page 1